Walleye Capital
SPRO icon

Walleye Capital’s Spero Therapeutics SPRO Stock Holding History

Walleye Capital’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40,009
Closed -$348K – 2705
2022
Q1 		$348K Buy
+40,009
New +$410K 0.01% 1217

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Walleye Capital's SPRO Position: Q2 2022 in Review

Walleye Capital sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 40,009 shares — an estimated $348K sold.

Walleye Capital first reported a position in SPRO in Q1 2022 and held it in 1 quarter. The position peaked at $348K in Q1 2022. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Walleye Capital reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Walleye Capital sold 40,009 Spero Therapeutics shares in Q2 2022, an estimated $348K.
  • Walleye Capital first reported a position in Spero Therapeutics in Q1 2022 and held it in 1 quarter.
  • Walleye Capital's Spero Therapeutics position peaked at $348K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.